|November 15, 2012|
|07:20 EDT||NUVA||NuVasive called a name to own at William Blair|
Following the company's investor meeting, William Blair calls NuVasive a name to own at current share levels. The firm expects the company's performance to improve going forward, starting in Q4.
News For NUVA From The Last 14 Days
|October 9, 2015|
|08:48 EDT||NUVA||Investors should look at several medtech stocks, says BMO Capital|
BMO Capital believes that macro issues have caused declines in medtech stocks. However, the firm thinks that the sector dealt with pricing issues years ago, while patient volumes are rising and larger cap names in the sector have "relatively stable revenue streams." BMO recommends that investors look at stocks with "reasonable multiples," such as Medtronic (MDT), those with new product pipelines such as Boston Scientific (BSX) and Edwards Lifesciences (EW), and those with small-cap product cycles, including Nevro (NVRO), NuVasive (NUVA), and Endologix (ELGX).
|06:53 EDT||NUVA||LDR Holding not a proxy for broader spine market, says Northland|
After the company preannounced Q3 revenue that came in slightly below the consensus, Northland analyst Mark Landy says LDR Holding (LDRH) is a not a proxy for the broader spine market. The vast majority of LDR's sales are from niche products, Landy tells investors in a research note. As such, he believes last night's news should not be extrapolated to NuVasive (NUVA) and K2M Group (KTWO). He thinks the consensus estimates for LDR's MOBI-C growth in 2015 may have been a "touch optimistic" given a slower than expected broadening of reimbursement for two-level use. He keeps an Outperform rating on LDR Holding with a $38 price target.
|October 7, 2015|
|11:32 EDT||NUVA||Leerink medical supplies/devices analyst holds analyst/industry conference call|
Subscribe for More Information
|October 6, 2015|
|10:00 EDT||NUVA||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: Communications Sales & Leasing (CSAL) upgraded to Overweight at Morgan Stanley... FedEx (FDX) upgraded on upcoming positive catalysts at Stifel... Mediaset (MDIUY) upgraded to Buy from Hold at HSBC... Melco Crown (MPEL) upgraded to Hold from Sell at Deutsche Bank... NuVasive (NUVA) upgraded to Buy at Canaccord... SJM Holdings (SJMHY) upgraded to Hold from Sell at Deutsche Bank... Select Medical (SEM) upgraded on expected EBITDA jump at Wells Fargo... Smart & Final Stores (SFS) upgraded to Overweight from Equal Weight at Barclays... Springleaf (LEAF) upgraded to Outperform from Market Perform at Keefe Bruyette... Tanger Factory (SKT) upgraded to Neutral from Underperform at BofA/Merrill.
|07:55 EDT||NUVA||NuVasive upgraded to Buy at Canaccord|
As reported previously, Canaccord upgraded NuVasive to Buy from Hold as they believe a current and projected strong U.S. macro environment for the broad spine market offsets tough comps and will continue to provide a solid tailwind. The firm also sees continued margin expansion and integration of its iGA platform strategy. Canaccord raised its price target to $58 from $52 on NuVasive shares.
|06:08 EDT||NUVA||NuVasive upgraded to Outperform from Market Perform at BMO Capital|
Subscribe for More Information
|06:07 EDT||NUVA||NuVasive upgraded to Buy from Hold at Canaccord|